Scholar Rock (NASDAQ:SRRK) Upgraded by UBS Group to Strong-Buy Rating

UBS Group upgraded shares of Scholar Rock (NASDAQ:SRRK) to a strong-buy rating in a research note published on Wednesday,Zacks.com reports.

Several other research firms have also commented on SRRK. Leerink Partners assumed coverage on Scholar Rock in a research report on Monday, September 15th. They set an “outperform” rating and a $51.00 price target on the stock. Barclays boosted their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Friday, November 14th. Finally, HC Wainwright decreased their price objective on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Five analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $49.77.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $41.67 on Wednesday. The company’s fifty day simple moving average is $40.45 and its 200-day simple moving average is $36.54. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 52 week low of $22.71 and a 52 week high of $48.28. The company has a market cap of $4.25 billion, a PE ratio of -13.23 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the business posted ($0.66) earnings per share. As a group, equities research analysts anticipate that Scholar Rock will post -2.42 EPS for the current year.

Insider Transactions at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $44.09, for a total value of $44,354.54. Following the completion of the sale, the director directly owned 32,908 shares of the company’s stock, valued at $1,450,913.72. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mo Qatanani sold 136,462 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total value of $6,169,447.02. Following the transaction, the insider directly owned 108,964 shares in the company, valued at approximately $4,926,262.44. This represents a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ramirez Asset Management Inc. acquired a new position in Scholar Rock in the third quarter worth $37,000. Penserra Capital Management LLC bought a new position in shares of Scholar Rock in the 3rd quarter worth about $56,000. Strs Ohio acquired a new position in shares of Scholar Rock in the 1st quarter valued at about $77,000. Bessemer Group Inc. grew its position in shares of Scholar Rock by 970.0% during the 3rd quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after buying an additional 2,105 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Scholar Rock during the second quarter worth about $94,000. 91.08% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).